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Summary
Objective: To examine the cross-sectional relationship between serum cartilage oligomeric matrix protein (COMP) and hip and knee clinical
signs and symptoms in a sample of adults without radiographic hip or knee osteoarthritis (OA).
Design: A total of 145 persons with available sera and no evidence of radiographic hip or knee OA (Kellgren–Lawrence grade 0) were
randomly selected from the Caucasian participants of the Johnston County Osteoarthritis Project. COMP was quantified by a competitive
ELISA assay with a monoclonal antibody 17-C10. Hip and knee clinical signs and symptoms were assessed by physical examination and
interview, and their associations with Ln COMP analysed with general linear models.
Results: After adjustment for age, gender, body mass index (BMI), and other symptomatic joints, mean Ln COMP was statistically
significantly higher among persons with hip-related clinical signs (P=0.018), among those with hip-related symptoms (P=0.046), and among
individuals meeting American College of Rheumatology clinical criteria for hip OA (P=0.021). There were no statistically significant
associations between any of the knee-related clinical signs and symptoms and Ln COMP.
Conclusion: Serum COMP may be useful as a biomarker of pre-radiographic hip joint pathology; its utility as a biomarker of pre-radiographic
knee joint pathology is unclear. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Cartilage oligomeric matrix protein (COMP) is a 524 kD
glycoprotein found in cartilage, synovium, and tendon1.
Elevated serum levels of COMP, potentially indicative of
alterations in cartilage and bone metabolism and/or syno-–
687vial inflammation, have been found in persons with knee
osteoarthritis (OA) compared with healthy persons2, in
persons with OA-related type II collagen gene mutations3,
and in patients with knee OA accompanied by synovitis,
compared with those with knee OA without synovitis4.
Mean serum COMP has been found to correlate with yearly
mean joint space narrowing in hip OA5, and a rise in serum
COMP has been observed in individuals with progressive
radiographic knee OA6,7. We recently reported elevations
in serum COMP concentration with the presence and
severity of radiographic knee OA, bilateral radiographic
knee OA, concomitant radiographic hip and knee OA, and
the number of knees and hips with radiographic evidence of
OA, in a large, population-based sample8. This report
expands our previous work by examining the relationship
between serum COMP concentration and hip- and knee-
related clinical signs and symptoms in those participants
without evidence of radiographic hip and knee OA.
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PARTICIPANTS
The Johnston County Osteoarthritis Project is an ongo-
ing population-based prospective study of hip and knee OA
in a rural North Carolina community. Details of the study
design and protocol have been published previously9.
Individuals aged 45 and older were recruited into the
project by probability sampling, without regard to prior joint
pain or OA status, between May 1991 and December 1997.
The institutional review boards of the University of North
Carolina at Chapel Hill and the Centers for Disease Control
and Prevention approved the study, which included two
interviewer-administered home interviews, a clinical and
radiographic assessment of hips and knees, and serum
sampling.
Of the 3189 project participants, 305 Caucasians met the
eligibility criteria for our present study, which were Kellgren
and Lawrence (K–L) radiographic grade of 0 (no radio-
graphic features of OA)10 in both hips and both knees and
a serum sample drawn at the time of radiography (the
analysis was limited to Caucasians for comparability to the
available literature to date; data on serum COMP in African-
Americans from this project will be reported separately).
The eligible participants were categorized by age (45–54
years, 55–64 years, and 65 years and older) and gender.
We randomly selected 24 or 25 subjects from each cat-
egory for evaluation of serum COMP concentration, for a
total of 145 study participants.RADIOGRAPHIC ASSESSMENT
Bilateral anteroposterior weight-bearing radiographs of
the knees were performed on all participants. Anteropos-
terior supine pelvis radiographs were obtained from women
50 years of age or older and from all men. A single
radiologist (JBR) scored all radiographs for K–L radio-
graphic grade10. Inter-rater (weighted kappa=0.859)
and intra-rater reliability (weighted kappa=0.886) for the
radiologist were high, as previously reported9.CLINICAL ASSESSMENT AND DEFINITION OF VARIABLES FOR
ANALYSIS
A clinical examination by a trained clinical examiner, was
performed on the same day as the radiographic assess-
ment. Clinical examination of each hip included report of
groin pain and hip pain on internal rotation; examiner’s
global assessment of the hip was recorded as normal or
mildly, moderately, severely abnormal. Each knee was
examined for five clinical signs: bony enlargement, crepi-
tus, effusion, bony tenderness, and soft tissue tenderness
at any of the anserine, infra-patellar, supra-patellar, and
pre-patellar sites. Examiner’s global assessment of the
knee was defined as for the hip.
For the purposes of defining hip and knee OA by
American College of Rheumatology (ACR) clinical cri-
teria11,12, hip flexion and internal rotation were each
measured to the nearest degree using a long-arm goniom-
eter, and the presence of morning stiffness (minutes) for
each hip and each knee was also recorded.
The presence of other symptomatic joints was deter-
mined during the clinical examination by report of joint
symptoms on a homunculus (shoulders, neck, upper-/mid-
back, lower-back, elbows, wrists, ankles, hands, feet).Height was measured in centimeters and weight in kilo-
grams using a balance beam scale, and body mass index
(BMI) was defined as weight in kilograms/height in meters2.
Symptoms of pain, aching, or stiffness in knees and hips
was assessed in identical fashion during an interview done
on average within 2 weeks of the clinical and radiographic
examination, with the question, ‘On most days do you have
pain, aching, or stiffness in your right [left] hip [knee]?’.
For analysis, hip symptoms were defined as the report of
groin pain or an affirmative response to the hip pain,
aching, or stiffness question above. Hip-related clinical
signs were defined as the presence of hip pain on internal
rotation. Knee symptoms were defined as an affirmative
response to the knee pain, aching, or stiffness question
above. Knee-related clinical signs were defined as the
presence of any one of the above five signs. Hip and knee
global assessments were each defined as normal vs abnor-
mal for hip and knee, respectively, and hip and knee OA by
ACR clinical criteria were defined accordingly11,12.ELISA ASSAY
Sera were separated and stored on ice immediately,
frozen to −20°C within 8 h of collection, and transferred
to −86°C for long-term storage. COMP was quantified by
an inhibition ELISA assay using monoclonal antibody
17-C108. Samples were analysed in duplicate, blinded, and
in random order; the means of the duplicate values for
COMP for each individual were used in analyses. Intra-
assay coefficient of variation was 3% and inter-assay was
9%.STATISTICAL ANALYSIS
All statistical analyses were performed using SAS 6.12
software13. Descriptive statistics were used to summarize
the non-normal distribution of serum COMP levels, includ-
ing the median, first quartile (Q1) and third quartile (Q3).
We used natural logarithmic transformation of COMP to
satisfy the assumptions underlying the use of general linear
model methodology. To evaluate the linear relationship of
Ln-transformed serum COMP with continuous variables,
we calculated Pearson correlation coefficients and per-
formed tests for correlation. Differences between means of
Ln COMP were assessed by the Student t-test.
Four separate linear models were used to assess the
relationship of Ln COMP with hip- and knee-specific vari-
ables for symptoms, clinical signs, global assessment, and
OA by ACR clinical criteria11,12, adjusted for age, gender,
BMI, and the presence of other symptomatic joints
statistically significantly associated with Ln COMP in age-,
gender-, and BMI-adjusted analyses. From every linear
model, we calculated the differences between adjusted
(least-squares) means and corresponding 95% confidence
intervals (95% CI).Results
Selected characteristics of the sample are depicted in
Table I. Serum COMP ranged from 292 ng/ml to 2291 ng/
ml, with an overall median of 959 ng/ml and first and third
quartile cut-points of 824 ng/ml and 1272 ng/ml, respect-
ively. The mean (S.D.) for Ln COMP was 6.92 ng/ml
(0.33 ng/ml). Serum Ln COMP was positively correlated
with age (r=0.35; P<0.0001) but not with BMI (r=0.03;
Osteoarthritis and Cartilage Vol. 10 No. 9 689P=0.691) or associated with gender (P=0.326). These
relationships persisted in all multivariable models.
The relationships of serum Ln COMP with hip and knee
symptoms are shown in Table II. Serum Ln COMP was
statistically significantly higher in the presence of hip symp-
toms (P=0.003), and this result remained statistically sig-
nificant after adjustment (Table II). In contrast, the
association with knee symptoms did not reach statistical
significance before or after adjustment. Similar results were
seen when assessing the relationship between Ln COMP
and hip and knee clinical signs (Table III).
Additionally, serum Ln COMP was slightly higher in those
with an abnormal hip global assessment (P=0.025) but was
unassociated with knee global assessment (P=0.238).
Neither of these associations was statistically significant
after adjustment.Although by definition, no participants had radiographic
OA of the hip or knee, 15% met the ACR clinical criteria for
hip OA and 19% met the ACR clinical criteria for knee OA.
Consistent with observations above, serum Ln COMP was
statistically significantly associated with hip OA by ACR
criteria (P=0.005), but not with knee OA by ACR criteria
(P=0.598). The relationship between Ln COMP and hip OA
by ACR clinical criteria remained statistically significant
after adjustment (P=0.021).
Of other reported symptomatic joints, serum Ln COMP
was positively associated with symptoms in the shoulder
(P=0.014), upper/mid back (P=0.033), and elbow
(P=0.045) in age-, gender-, and BMI-adjusted analysis, but
none of these associations was statistically significant in
any models after further adjustment, save for an associ-
ation between Ln COMP and shoulder symptoms
(P=0.035) in the model assessing hip and knee OA by ACR
criteria.Table I
Selected characteristics of the sample, N=145
% female 50
% 45–54 years 33.3
% 55–64 years 33.3
% 65 years and older 33.3
Age range (years) 45–85
Mean (S.D.) age (years) 60.2(9.8)
Mean (S.D.) body mass index (kg/m2) 27.2(4.8)Table II
Serum COMP levels and hip and knee symptoms
Values N COMP
median
(Q1–Q3)
Difference of
Ln COMP
adjusted means
(95% CI)*
P value*
Hip symptoms No 89 919 0.123 0.046
(771–1108) (0.002, 0.244)
Yes 54 1104
(863–1415)
Knee symptoms No 96 951 −0.058 0.345
(810–1231) (−0.178, 0.063)
Yes 48 1003
(817–1340)
*From linear model for Ln COMP containing variables for hip symptoms, knee symptoms, age, gender, body
mass index, shoulder, upper/mid back, and elbow symptoms.Table III
Serum COMP levels and hip and knee clinical signs
Values N COMP
median
(Q1–Q3)
Difference of
Ln COMP
adjusted means
(95% CI)*
P value*
Hip clinical signs No 105 924 0.146 0.018
(793–1131) (0.025, 0.266)
Yes 35 1270
(870–1506)
Knee clinical signs No 42 959 −0.005 0.932
(841–1263) (−0.115, 0.105)
Yes 99 947
(796–1293)
*From linear model for Ln COMP containing variables for hip clinical signs, knee clinical signs, age, gender,
body mass index, and shoulder, upper/mid back, and elbow symptoms.Discussion
Ours is the first study to investigate the relationship
between serum COMP concentration and symptoms and
clinical signs of hip and knee pathology among persons
with no radiographic evidence of hip and knee OA. Our
finding of elevated serum COMP associated with hip symp-
toms and clinical signs in the absence of radiographic
abnormality may reflect an underlying pathological process
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olism or synovitis. Increased serum concentrations of
COMP have been observed in Del1 mice (which harbor a
short deletion in a type II collagen transgene) at the age of
4 months, correlating temporally with the onset of cartilage
degeneration14. This study and our own suggest that
serum COMP concentration may be a useful marker for
altered cartilage or other joint tissue metabolism with devel-
oping joint pathology of the hip. While it is well-recognized
that radiographic OA and joint symptoms may be discord-
ant15, epidemiological studies have indicated that knee
pain predicts incident radiographic knee OA16. Joint pain
has been found to be associated with muscle weakness17,
which may occur before OA is apparent radiographically18.
Muscle dysfunction may be a cause of OA and under these
circumstances, altered joint load could contribute to altered
cartilage catabolism, reflected in increased serum COMP
concentration. Subclinical cartilage degeneration could in-
itiate synovitis in response to cartilage matrix components
in the joint fluid, causing pain. Inflamed synovium is a
potential source of COMP4,9, although it appears that the
concentration of COMP in cartilage exceeds that found in
other joint tissues. Petersson and colleagues investigated
the relative content of aggrecan and COMP in synovial fluid
lavage samples from persons with knee pain with or without
radiological knee OA defined by joint space narrowing;
COMP concentration was higher among persons with
radiological evidence of joint pathology20. However, differ-
ences in absolute levels of aggrecan and COMP between
those radiographically negative individuals with and without
knee pain could not be compared. We have ourselves
detected highest serum COMP concentrations among
persons with radiographic OA8.
We found statistically significant associations between
serum Ln COMP and hip-related symptoms, but not knee-
related symptoms. This was surprising, since the hip symp-
tom question was asked in identical fashion to the knee
symptom question, and it was associated with serum
COMP levels even though no specific location for the hip
symptoms was sought with this question. The presence of
groin pain was strongly associated with the hip pain,
aching, or stiffness question, and we did note a somewhat
stronger association between groin pain and serum Ln
COMP than between the less-specific hip symptoms ques-
tion and serum Ln COMP (data not shown). However,
including groin pain in the hip symptoms definition did not
change the relationships observed with hip symptoms
defined by the hip pain, aching, or stiffness question alone.
Further, hip-related clinical signs and hip OA defined by
ACR clinical criteria, were also associated with serum Ln
COMP. Serum COMP concentration has previously been
shown to be higher in patients with bilateral (compared with
unilateral) hip OA and to correlate with hip joint space width
and yearly mean joint space narrowing5.
Serum Ln COMP was not associated with knee-related
symptoms, clinical signs, or knee OA defined by ACR
clinical criteria. This may be because some of the knee-
related clinical signs may be more common and less
specific than the hip-related signs we evaluated. Knee soft
tissue tenderness, but not knee swelling, was associated
with serum COMP level in another cohort with established
knee OA4, but that study did not simultaneously evaluate
hip clinical signs and symptoms. Other explanations for the
stronger association between serum COMP and hip-related
variables than knee-related variables may include differ-
ences in specificity of the K–L grading system for the hip
and knee, lack of radiographic information about the patel-lofemoral joint, and use of the less precise K–L radio-
graphic grading system, rather than direct measurement of
joint space, to define radiographic OA, possibly resulting in
some degree of misclassification of radiographic OA status.
Although the associations we observed between serum
COMP and symptoms and clinical signs of hip pathology
were not particularly strong, they were consistent across
varying definitions, including symptoms, clinical signs and
hip OA by ACR clinical criteria. In addition, adjustment for
other symptomatic joints did little to alter the relationships
noted for serum COMP and hip variables. For these
reasons, we doubt that the associations between serum
COMP and hip symptoms and clinical signs we observed
were related instead to OA at other joint sites we did
not investigate radiographically. Nonetheless, our results
should be confirmed in other populations before firm
conclusions can be drawn.
Our results have potential clinical implications and sug-
gest that closer attention should be given to radiographi-
cally unaffected persons with hip symptoms and clinical
signs, who may merit further evaluation or treatment for hip
joint pathology. However, serum COMP cannot be used
diagnostically or prognostically in an individual patient at
this time because of lack of normative datasets and valid
means of quantifying OA globally in an individual. Our
results suggest further research into the OA process,
imaging, and the use of serum biomarkers. For example,
examination of the relationship between serum COMP
concentration and OA status assessed with more sensitive
OA definitions and/or joint imaging techniques, such as
magnetic resonance imaging, might be a logical next step.
Longitudinal analyses, to be done with the completion of
the follow-up phase of the Johnston County Osteoarthritis
Project, will elucidate whether increased serum COMP
concentrations with concurrent joint symptoms might be
reversible or instead portend the development of incident
radiographic OA. Although our subjects were radiographi-
cally negative for both knees and hips (a more stringent
requirement than any other radiographic study of serum
COMP concentration to date, as most have focused only on
radiographic knee OA), our results suggest that control
subjects for future studies of OA and serum COMP should
not only lack radiographic OA, but might in addition, also
lack symptoms and clinical signs of OA.Acknowledgments
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